Severe aortic stenosis is a serious disease. Until recently, the only
treatment was open-heart surgery to replace the diseased aortic valve,
leaving many patients no alternative if surgery was not possible or too
risky. Today, there are new approaches to valve replacement, and
Lankenau is at the forefront of these treatment advances.
Transcatheter aortic valve replacement (TAVR) offers new hope for
patients with severe aortic stenosis who are inoperable or at high risk
for undergoing surgery. Now, when aortic valve replacement is needed,
TAVR may be an option. This groundbreaking therapy is available at the
Valve Clinic at Lankenau Medical Center using the first FDA-approved
TAVR therapy—the Edwards SAPIEN transcatheter heart valve.
TAVR therapy with the SAPIEN valve is available only at medical centers
that meet criteria to perform the procedure. Experience in advanced
techniques for evaluation and treatment of heart vessel and valve
diseases is a key factor in being chosen to offer TAVR therapy.
The cardiovascular surgeons and interventional cardiologists at the
Lankenau Medical Center Valve Clinic have extensive experience and
advanced skill in treating complex disorders of the vessels, valves, and
other structures of the heart. TAVR is the latest of many minimally
invasive treatment options our specialists offer to patients with
For more information, call 1.866.CALL.MLH.